Dosage strategies for delaying resistance emergence in heterogeneous tumors
Drug resistance in cancer treatments is a frequent problem that, when it arises, leads to failure in therapeutic efforts. Tumor heterogeneity is the primary reason for resistance emergence and a precise treatment design that takes heterogeneity into account is required to postpone the rise of resist...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | FEBS Open Bio |
Subjects: | |
Online Access: | https://doi.org/10.1002/2211-5463.13129 |
id |
doaj-ac786fddba9444c9b4215c88917dbb5c |
---|---|
record_format |
Article |
spelling |
doaj-ac786fddba9444c9b4215c88917dbb5c2021-05-03T11:42:20ZengWileyFEBS Open Bio2211-54632021-05-011151322133110.1002/2211-5463.13129Dosage strategies for delaying resistance emergence in heterogeneous tumorsVahideh Vakil0Wade Trappe1Wireless Information Network Laboratory (WINLAB) Rutgers, The State University of New Jersey New Brunswick NJ USAWireless Information Network Laboratory (WINLAB) Rutgers, The State University of New Jersey New Brunswick NJ USADrug resistance in cancer treatments is a frequent problem that, when it arises, leads to failure in therapeutic efforts. Tumor heterogeneity is the primary reason for resistance emergence and a precise treatment design that takes heterogeneity into account is required to postpone the rise of resistant subpopulations in the tumor environment. In this paper, we present a mathematical framework involving clonal evolution modeling of drug‐sensitive and drug‐resistant clones. Using our framework, we examine delaying the rise of resistance in heterogeneous tumors during control phase of therapy in a containment treatment approach. We apply pharmacokinetic/pharmacodynamic (PKPD) modeling and show that dosage strategies can be designed to control the resistant subpopulation. Our results show that the drug dosage and schedule determine the relative dynamics of sensitive and resistant clones. We present an optimal control problem that finds the dosing strategy that maximizes the delay in resistance emergence for a given period of containment treatment.https://doi.org/10.1002/2211-5463.13129clonal evolutioncontainmentdosage strategydrug resistanceoptimal control |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vahideh Vakil Wade Trappe |
spellingShingle |
Vahideh Vakil Wade Trappe Dosage strategies for delaying resistance emergence in heterogeneous tumors FEBS Open Bio clonal evolution containment dosage strategy drug resistance optimal control |
author_facet |
Vahideh Vakil Wade Trappe |
author_sort |
Vahideh Vakil |
title |
Dosage strategies for delaying resistance emergence in heterogeneous tumors |
title_short |
Dosage strategies for delaying resistance emergence in heterogeneous tumors |
title_full |
Dosage strategies for delaying resistance emergence in heterogeneous tumors |
title_fullStr |
Dosage strategies for delaying resistance emergence in heterogeneous tumors |
title_full_unstemmed |
Dosage strategies for delaying resistance emergence in heterogeneous tumors |
title_sort |
dosage strategies for delaying resistance emergence in heterogeneous tumors |
publisher |
Wiley |
series |
FEBS Open Bio |
issn |
2211-5463 |
publishDate |
2021-05-01 |
description |
Drug resistance in cancer treatments is a frequent problem that, when it arises, leads to failure in therapeutic efforts. Tumor heterogeneity is the primary reason for resistance emergence and a precise treatment design that takes heterogeneity into account is required to postpone the rise of resistant subpopulations in the tumor environment. In this paper, we present a mathematical framework involving clonal evolution modeling of drug‐sensitive and drug‐resistant clones. Using our framework, we examine delaying the rise of resistance in heterogeneous tumors during control phase of therapy in a containment treatment approach. We apply pharmacokinetic/pharmacodynamic (PKPD) modeling and show that dosage strategies can be designed to control the resistant subpopulation. Our results show that the drug dosage and schedule determine the relative dynamics of sensitive and resistant clones. We present an optimal control problem that finds the dosing strategy that maximizes the delay in resistance emergence for a given period of containment treatment. |
topic |
clonal evolution containment dosage strategy drug resistance optimal control |
url |
https://doi.org/10.1002/2211-5463.13129 |
work_keys_str_mv |
AT vahidehvakil dosagestrategiesfordelayingresistanceemergenceinheterogeneoustumors AT wadetrappe dosagestrategiesfordelayingresistanceemergenceinheterogeneoustumors |
_version_ |
1721482456050171904 |